» Articles » PMID: 31008982

Case Report of Long-term Survival with Metastatic Triple-negative Breast Carcinoma: Treatment Possibilities for Metastatic Disease

Overview
Specialty General Medicine
Date 2019 Apr 23
PMID 31008982
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: Breast cancer is the most common as well as one of the most devastating cancers among women in the United States. Prognosis is poor for patients with metastatic breast cancer, especially for patients with so-called "triple-negative" disease. The lack of effective therapies for metastatic triple-negative breast cancer outlines the need for novel and innovative treatment strategies.

Patient Concerns: A 58-year-old underwent a mastectomy which revealed a recurrent triple-negative breast carcinoma. Afterward, she presented with a growing mass in her left axilla and chest wall. A computed tomography scan showed axillary and supraclavicular adenopathy, nodules in the left upper and lower lobe of the lungs, and 2 areas of disease in the liver. A bone scan showed lesions in the ribs.

Diagnosis: The patient was diagnosed with a recurrent metastatic triple-negative breast carcinoma that spread to the lung, liver, and bones.

Interventions: The patient was treated with metronomic chemotherapy, sequential chemotherapy regimens, and immunotherapy.

Outcomes: The patient is now over 15 years out from her diagnosis of metastatic disease without any evidence of recurrent disease, likely due to the patient's treatment strategy which included sequential metronomic chemotherapy regimens and immunotherapy.

Lessons: Sequential metronomic chemotherapy regimens in combination with immunotherapy might be an effective treatment option for patients with metastatic triple-negative breast cancer. We hope that this case can provide some guidance for the treatment of metastatic triple-negative breast cancer and motivate research that can potentially lead to more cases of long-term survival for patients who develop this dismal disease.

Citing Articles

Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.

Jan N, Sofi S, Qayoom H, Shabir A, Haq B, Macha M Heliyon. 2024; 10(3):e24670.

PMID: 38314272 PMC: 10837507. DOI: 10.1016/j.heliyon.2024.e24670.


Thymoquinone Inhibition of Chemokines in TNF-α-Induced Inflammatory and Metastatic Effects in Triple-Negative Breast Cancer Cells.

Adinew G, Messeha S, Taka E, Mochona B, Redda K, Soliman K Int J Mol Sci. 2023; 24(12.

PMID: 37373025 PMC: 10298461. DOI: 10.3390/ijms24129878.


Hedgehog Signaling Regulates Treg to Th17 Conversion Through Metabolic Rewiring in Breast Cancer.

Hinshaw D, Benavides G, Metge B, Swain C, Kammerud S, AlSheikh H Cancer Immunol Res. 2023; 11(5):687-702.

PMID: 37058110 PMC: 10159910. DOI: 10.1158/2326-6066.CIR-22-0426.


A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation.

West J, Adler F, Gallaher J, Strobl M, Brady-Nicholls R, Brown J Elife. 2023; 12.

PMID: 36952376 PMC: 10036119. DOI: 10.7554/eLife.84263.


(Forssk.) Sch.Bip Flower Dichloromethane Extract Exerts Anti-Proliferative and Pro-Apoptotic Properties in Human Triple-Negative Breast Cancer (MDA-MB-231) Cells: In Vitro and In Silico Studies.

Alshuail N, Alehaideb Z, Alghamdi S, Suliman R, Al-Eidi H, Ali R Pharmaceuticals (Basel). 2022; 15(9).

PMID: 36145281 PMC: 9506496. DOI: 10.3390/ph15091060.


References
1.
Garcia-Teijido P, Cabal M, Pelaez Fernandez I, Perez Y . Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol. 2016; 10(Suppl 1):31-9. PMC: 4822722. DOI: 10.4137/CMO.S34540. View

2.
Hamilton E, Clay T, Blackwell K . New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Invest. 2011; 29(8):533-41. DOI: 10.3109/07357907.2011.605413. View

3.
Dean-Colomb W, Esteva F . Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. Semin Oncol. 2008; 35(2 Suppl 2):S31-8. DOI: 10.1053/j.seminoncol.2008.02.008. View

4.
Zhang X, Zang J, Xu J, Bai C, Qin Y, Liu K . Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest. 2011; 140(1):117-126. DOI: 10.1378/chest.10-2745. View

5.
Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View